New FDI World Dental Federation Care Pathway Promotes Dentist-patient Collaboration to Manage Partial Tooth Loss

Food and Healthcare Press Releases Thursday September 5, 2019 13:00
SAN FRANCISCO--5 Sep--PRNewswire/InfoQuest
Today during the ADA FDI World Dental Congress in San Francisco, USA, FDI World Dental Federation (FDI) released its latest resources on the treatment and care of patients with partial tooth loss.

Rather than losing all their teeth as they age, more and more dental patients are greeting old age with a number of their teeth still intact. Having more teeth has led to the advent of a relatively new dental patient group: partially dentate patients. These patients have one or more missing teeth, which are either congenitally absent or have been extracted due to disease, trauma or surgery.

FDI has launched a series of tools to offer this patient group a tailored, comprehensive approach to treatment and care. These include the Collaborative Care Continuum: The 3Cs pathway for partially dentate patients white paper, as well as guidelines designed for oral health professionals that support patient-practitioner communication and offer advice to manage patients who are partially dentate.

Even partial tooth loss affects many aspects of life and may:
  • Limit the enjoyment of certain foods;
  • Undermine self-confidence;
  • Lead to social isolation and affect relationships with others.

"Our work is focused on a personalized approach to managing partially dentate patients," said FDI President Dr Kathryn Kell. "We know that good patient-practitioner communication is linked not only to increased patient satisfaction, but also with better adherence to treatment."

Caring for a partially dentate patient follows a three-step process called the collaborative care continuum, or the 3Cs care pathway. This pathway includes:
  • A pre-treatment and assessment phase;
  • A treatment phase; and
  • A post-treatment and long-term care phase.
Oral health professionals should place equal importance on each of these three phases and organize their treatment and care plan along this continuum.

FDI's work on partially dentate patients is supported by GSK. "We are excited to collaborate with FDI to improve the treatment and care for this unique group of patients," said Dr Roshan Varghese, Global Medical Affairs Director, Denture Care, GSK. We believe that the most successful treatment relies on comprehensive patient education. A focus on long-term care and maintenance needs to become an integral part of any treatment for partially dentate patients."

About FDI World Dental Federation

FDI is the main representative body for more than one million dentists worldwide, with a vision of leading the world to optimal oral health. Its membership comprises some 200 national member associations and specialist groups in over 130 countries. FDI is based in Geneva, Switzerland.

About GSK

GlaxoSmithKline is a science-led healthcare company with a special purpose: to help people do more, feel better, live longer. We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Oral Health, Pain Relief, Cold, Flu & Allergy +OTC Derm and Wellness categories.

Media contact: Charanjit Jagait, FDI Communications & Advocacy Director Tel: +41 79 796 76 13

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (, a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics